Head-to-head evidence
HDG1901 vs IcoSema
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
HDG1901
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
NCT06739044 · Phase 3 · completed
The trial randomized 494 participants to HDG1901 or active Ozempic treatment, but neither participants nor investigators were blinded. Its primary endpoint was change in HbA1c, a surrogate measure, and the registry does not report whether the comparison met its objective, supporting a moderate evidence grade.
Caveat: source is secondary industry coverage that does not cite the trial registry number; attribution rests on sponsor/program match only.
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HDG1901's landscape · IcoSema's landscape